Search results for: Maria Lowe
Filter search results
Exploring Variations in the Opportunity Cost Cost-effectiveness Threshold by Clinical Area: Results from a Feasibility Study in England
20 March 2019
…PCTs operating efficiently in a PBC tend to have lower rates of mortality, and for most disease areas, the lower the mortality, the harder it is to achieve additional reductions….
Victor R. Fuchs Award for 2020 Goes to Patricia Danzon
23 June 2020
…she shows how external referencing by higher-price (usually also higher-income) countries leads to delays and non-launch of new drugs in lower-price (usually also lower-income) referenced countries. The most promising approach…
A NICE Wind of Change? The What and So What of the NICE Methods Consultation
7 December 2020
…stated in the current methods guide, to 1.5%. The use of lower discount rates implies an increase in the importance that NICE gives to future costs and health benefits. The…
OHE is Launching a New Series to Explore the Latest Attempts to Reduce the Cost of US Healthcare
7 September 2021
…need for lower drug prices, President Biden has taken up the gauntlet and put the cost of prescription drugs front and centre. US healthcare reform is frequently on the US…
Does the New CBO Report Change Anything?
15 September 2021
…1: H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act CBO report 2: CBO’s Simulation Model of New Drug Development: Working Paper 2021-09 The other major change is that…
Estimating the Impact of U.S. Drug Price-setting Policies on Innovation Is Challenging, Even for the Congressional Budget Office
22 June 2022
…J., Firth, I., Hampson, G., Jofre-Bonet, M., Garau, M., Garrison, L. and Cookson, G. (2021) The Lower Drug Costs Now Act and Pharmaceutical Innovation. OHE Consulting Report. Available from https://www.ohe.org/publications/lower-drug-costs-now-act-and-pharmaceutical-innovation….
Incentives to follow Best Practice in Health Care
1 February 2015
There has been long-standing interest in the use of incentives to encourage delivery of high-quality health care services at the lowest feasible cost. There has been long-standing interest in the…
Review of CRA’s Report “Assessing the Economic Impacts of Changing Exemption Provisions During Patent and SPC Protection in Europe”
1 January 2018
…this. The correct industrial strategy for the EU may well be to focus on the development, manufacture and export of innovative products, rather than on lower value generics where EU…
Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals
1 July 2018
…illustrated how IBP could lead to lower prices for lower value indications, while Chandra and Garthwaite (2017) argued that IBP would lead to higher prices overall. The key differences arose…